Clinical trials · Iowa
Gastroenteropancreatic Neuroendocrine Tumor clinical trials in Iowa
We’re tracking 6 recruiting gastroenteropancreatic neuroendocrine tumor studies with a site in Iowa — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Iowa
- NCT05773274RecruitingPhase 2
Retreating with 177Lu-DOTATATE radiation versus usual treatment
This trial tests whether repeating a targeted radioactive treatment (177Lu-DOTATATE) works better than standard options in people with metastatic gastroenteropancreatic neuroendocrine tumors. It may help by controlling tumor growth after the first round of this therapy stops working.
Ankeny, IowaAges 18 years+ - NCT05477576RecruitingPhase 3
Lu-177–treated NET patients: new drug versus standard care
This Phase 3 trial tests RYZ101 versus standard of care in people with inoperable, well-differentiated SSTR-positive GI or pancreas neuroendocrine tumors (NETs) that keep growing after Lu-177 SSA. It may help by improving tumor control after your prior targeted radiation treatment.
Iowa City, IowaAges 18 years+ - NCT05636618RecruitingPhase 1/Phase 2
Targeted radiation for certain receptor-positive tumors
This trial tests a targeted form of radiation made to stick to specific “somatostatin receptor” markers on tumors. It is designed for people with advanced, receptor-positive neuroendocrine tumors or meningioma who may have had prior treatments and need more options.
Iowa City, IowaAges 18–90 - NCT06395402RecruitingPhase 2
Personalized dosing of lutathera for neuroendocrine tumors
This trial tests a personalized way to give a radioactive drug called Lutathera to people with neuroendocrine tumors (NETs). The goal is to see if adjusting the dose based on how your body absorbs it can be more effective.
Iowa City, IowaAges 18 years+ - NCT07165132RecruitingPhase 1
RYZ401 for advanced neuroendocrine tumors
This trial tests an experimental drug called RYZ401 for people with advanced neuroendocrine tumors (NETs) that show a certain marker on scans. The drug is designed to target the tumor cells directly and may be a new option for those who have not had a similar type of targeted radiation therapy.
Iowa City, IowaAges 18 years+ - NCT07006727RecruitingPhase 1
Targeted radiation therapy for DLL3-positive advanced cancers
This study tests a new targeted radiation therapy (called [225Ac]Ac-ETN029) for people with advanced cancers that have a protein called DLL3 on their cells. The treatment is designed to deliver radiation directly to cancer cells, and the goal is to see if it is safe and effective.
Iowa City, IowaAges 18–100
Where these studies are running in Iowa
Institutions with a site for the recruiting gastroenteropancreatic neuroendocrine tumor studies listed above.
- Research Facility · 2 studies
- University of Iowa · 2 studies
- Iowa Methodist Medical Center
- UI Health Care Mission Cancer and Blood
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
- UI Health Care Mission Cancer and Blood - Waukee Clinic
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
- University of Iowa/Holden Comprehensive Cancer Center
What taking part in a gastroenteropancreatic neuroendocrine tumor study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Gastroenteropancreatic Neuroendocrine Tumor trials in other states
Common questions
- Are there gastroenteropancreatic neuroendocrine tumor clinical trials in Iowa?
- Yes. We're currently tracking 6 recruiting gastroenteropancreatic neuroendocrine tumor studies with a site in Iowa, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a gastroenteropancreatic neuroendocrine tumor study in Iowa?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Iowa to take part?
- Not necessarily. These studies have a site in Iowa, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a gastroenteropancreatic neuroendocrine tumor trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New gastroenteropancreatic neuroendocrine tumor studies open in Iowa regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.